Comparison of efficacy in renoprotection between Azilsartan medoxomil and Enalapril : A randomized, open-labeled controlled trial

A total of 50 patients with hypertension and albuminuria were recruited. At the end of treatment, systolic blood pressure level was significantly reduction in the azilsartan group compared with the enalapril group. In addition, at 24-week, significant reduction in median UACR of azilsartan group compared to the enalapril group was observed. There was no statistically significant difference between the two groups in hyperkalemia, estimated GFR, acute kidney injury and serious adverse events.